Canagliflozin
Who holds supplier records for Canagliflozin? 21 organisations hold a current record for Canagliflozin: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (12) and China (7); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Canagliflozin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/canagliflozin
Reading the evidence
- 21 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
12 of the 19 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 13 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Canagliflozin expires 26 Aug 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (21)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Canagliflozin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- DASAMI LAB PRIVATE LTDIndia Company GMP cert on recordActive DMF 30972, 31231 · latest filing Mar 2017
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 30771, 34306 · latest filing Nov 2019
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 29496, 29867 · latest filing Oct 2015
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 31290, 34051 · latest filing Sept 2019
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 31161 · latest filing Dec 2016
- Alkem Laboratories LimitedIndia Company GMP cert on recordActive DMF 30941 · latest filing Sept 2016
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 30964 · latest filing Sept 2016
- BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTDChinaActive DMF 29434 · latest filing Jun 2015
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 36739 · latest filing Jan 2022
- CHONGQING CARELIFE PHARMACEUTICAL CO LTDChinaActive DMF 30853 · latest filing Aug 2016
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 31025 · latest filing Sept 2016
- FUXIN LONG RUI PHARMACEUTICAL CO LTDActive DMF 33376 · latest filing Dec 2018
- INDOCO REMEDIES LTDIndia Company GMP cert on recordActive DMF 30951 · latest filing Oct 2016
- Jiangxi Synergy Pharmaceutical Co., LtdChinaActive DMF 38734 · latest filing Sept 2023
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 31233 · latest filing Jan 2017
- LUPIN MANUFACTURING SOLUTIONS LTDActive DMF 31504 · latest filing Apr 2017
- Macleods Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 30753 · latest filing Sept 2016
- Shanghai Desano Chemical Pharmaceutical Co., LtdChinaActive DMF 30366 · latest filing Dec 2015
- Zhejiang Huahai Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 30879 · latest filing Sept 2016
- Zhejiang Huayi Pharmaceutical Co., Ltd.ChinaActive DMF 40144 · latest filing Jul 2024
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 32226 · latest filing Nov 2017
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (2)
Organisations whose Type II DMFs for Canagliflozin are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- China · Inactive DMF 39703 · filed Mar 2024
- India · Inactive DMF 30449 · filed Apr 2016
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Canagliflozin). The latest listed patent expires 26 Aug 2029. The latest listed exclusivity runs to 18 Jun 2028. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion.
Chemical identity
- IUPAC name
- bis((2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol);hydrate
- Canonical SMILES
- CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O
- InChIKey
- VHOFTEAWFCUTOS-TUGBYPPCSA-N
- Synonyms
- Invokana API, canagliflozin hemihydrate, canagliflozin hydrate, invokamet component canagliflozin, invokana, jnj-24831754-zae, jnj-28431754-aaa
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Sodium-Glucose Cotransporter 2 Inhibitor
- Mechanism of action
- P-Glycoprotein Inhibitors; Sodium-Glucose Transporter 2 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Canagliflozin?
21 organisations hold an active US FDA Type II Drug Master File or a CEP for Canagliflozin: DASAMI LAB PRIVATE LTD (India), MATRIX PHARMACORP PRIVATE LTD (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), Sun Pharmaceutical Industries Limited (India), Alembic Pharmaceuticals Limited (India), Alkem Laboratories Limited (India), APITORIA PHARMA PRIVATE LTD (India) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (China), and 13 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Canagliflozin Drug Master Files are active?
DASAMI LAB PRIVATE LTD (DMF 30972, 31231), MATRIX PHARMACORP PRIVATE LTD (DMF 30771, 34306), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 29496, 29867), Sun Pharmaceutical Industries Limited (DMF 31290, 34051), Alembic Pharmaceuticals Limited (DMF 31161), Alkem Laboratories Limited (DMF 30941), APITORIA PHARMA PRIVATE LTD (DMF 30964) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (DMF 29434) and 13 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Canagliflozin records mean?
2 organisations have only inactive Type II DMFs for Canagliflozin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Canagliflozin?
Yes. The latest patent listed for an approved US product containing Canagliflozin expires 26 Aug 2029, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Canagliflozin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Canagliflozin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.